I will be presenting at the VRBPAC meeting at ~1:30 pm EST today.

Posted here is a link to listen to/watch my speech and all other 20 speeches!

Again my beloved subscribers! I apologize for my silence. I have simply just been busy punching the face of injustice. And other stuff.

The Vaccines and Related Biological Products Advisory Committee (VRBPAC) April 6, 2022 Meeting allows an Open Public Hearing to enable members of the public to voice concerns, opinions or present data to the voting members.

You can watch/listen to me here at 1:30 pm EST and please do listen to all 21 speakers!! give their 3-minute presentations. It’ll be an historic hour. I heard that many of the 20 have been injured by the COVID-19 injectable products. I am speaking first and this is my speech.

VRBPAC discussion of considerations for use of COVID-19 vaccine booster doses and the process for COVID-19 vaccine strain selection to address current and emerging variant viruses

April 6th, 2022

This is my third time presenting data in the context of VRBPAC meetings. Thank you for having me.

The last time I presented on October 26th, 2021, the Advisory Committee Voting Members voted 16 to 0 (with 1 abstention) on injecting 5-11-year-old children across the United States with COVID-19 injectable products. It felt statistically implausible for the voting to be skewed 100% in one direction and with all due respect, I was left feeling as though I had just spent my time going through an inconsequential ‘exercise’ rather than a meaningful democratic process.

I decided to speak again today, however, because even though I have little faith in the system, I still have faith in people.

I have no conflicts of interest to declare.

Slide 3

In preparation for my 3-minute presentation today, I read the Event Materials at the bottom of the FDA online site where the announcement for this meeting is posted. Listed in the Event Materials, there are 2 pdf files posted and available for download that came to my attention. One is entitled “Waiver to Allow Participation in an FDA Advisory Committee” and the other “U.S. FDA Advisory Committee Member Acknowledgment of Financial Interests”.

At least one of the Advisory Committee Temporary Voting Members sitting before us today is, in fact, conflicted financially.

Said voting member has identified a personal financial interest as well as financial interests of his employer, which can be affected by the particular matter before the committee. The latter financial interests are imputed to him under the federal conflict of interest statute, 18 U.S.C. § 208.

Although no one would doubt said stand-in judge’s excellent and unique qualifications and expertise on such matters as these, the expertise is not in question. The conflict of interest is, in my humble opinion. The Waiver that allows him to be a temporary voting member today was based partially on the fact that quote: ‘it would be impossible to replace [him]’. I do not believe this to be true. There are certainly many excellent and exceedingly qualified experts able to serve as a temporary voting member, who are not financially conflicted.

This, in my opinion, would allow for a therefore unbiased judging panel standing before us, ready to vote judiciously on this very sensitive matter.

It is my opinion that in order to honor fiduciary responsibility, it should never be the case that ‘expertise’ can be used as a reason to waive a conflict of interest, financial or otherwise. A conflict of interest, by definition, means that judgment or decisions could very well be compromised by the conflict, which is why our government agencies regulate them.

If a ‘yes’ vote means personal and professional financial gain, then why wouldn’t one vote ‘yes’?

I believe that precisely because of the sensitivity of this subject matter that it is not serving the public to have conflicted parties as voting members.

This is the very same committee that voted to recommend to the FDA to license the Rotashield vaccine in February 11, 1998 that ended up being withdrawn in 1999 due to a proven causal link to intussusception.

Slide 2

My original intention today was to present an update on adverse event data from the VAERS government database to show that the rates of reporting are not decreasing. In fact, they are continuing to increase in the context of the COVID-19 injectable products. I will simply leave you with this summary slide.

Thank you for your time again.

Stay tuned for my Defeat the Mandates speech coming up on Sunday, April 10th!